Securities Fraud Complaint Filed Against Talis Biomedical (TLIS)
A securities fraud lawsuit has been filed against Talis Biomedical Corporation (NASDAQ: TLIS) for potential securities violations on behalf of shareholders who purchased common stock pursuant to the registration statement and prospectus issued in connection with the company’s IPO in February 2021. The release of potentially misrepresentative and misleading information, as well as failure to […]